A description of warfarin and new oral anticoagulant utilization patterns including initiation, switching, and discontinuation: Phase 3 of the BI/BWH Pradaxa study program (Anticoagulant utilization pattern)

Study identification

• EU PAS number:
  EUPAS3064
• Study ID:
  31549
• Official title and acronym:
  A description of warfarin and new oral anticoagulant utilization patterns including initiation, switching, and discontinuation: Phase 3 of the BI/BWH Pradaxa study program (Anticoagulant utilization pattern)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study plans to describe utilization patterns for oral anticoagulants over time in patients with non-valvular atrial fibrillation at risk for stroke using electronic claims data from a US commercial insurance database
• Study status:
  Finalised

Research institutions and networks

Institutions

Brigham and Women's Hospital

Study timelines

Date when funding contract was signed

Planned: 01/06/2012

Actual: 01/06/2012

Study start date

Planned: 18/04/2013

Actual: 17/04/2013

Data analysis start date

Planned: 22/04/2013

Actual: 22/04/2013

Date of interim report, if expected

Planned: 30/06/2013

Date of final study report

Planned: 31/07/2017

Actual: 20/09/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable